Kyverna Therapeutics, Inc. Common Stock (KYTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $319.27M
Last updated: Nov 17, 2026 at 11:06 AM ET
Kyverna Therapeutics, Inc. Common Stock (KYTX) Stock Forecast
Analysts expect Kyverna Therapeutics, Inc. Common Stock (KYTX) to earn -$2.77 per share in the fiscal year ending Dec 31, 2026. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 33.3% |
| Buy | 4 | 66.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$2.77
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$3.17
- EPS consensus, revenue $17.20M
- Next report
- Mar 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.77 | -$3.02 to -$2.62 | 5 | N/A | N/A | 5 |
| Dec 31, 2027 | -$3.17 | -$3.74 to -$2.71 | 5 | $17.20M | $4.30M to $41.09M | 6 |
Quarterly Estimates
The EPS consensus falls from -$0.79 for the quarter ending Dec 31, 2026 to -$0.80 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.79 | -$0.97 to -$0.71 | 8 | N/A | N/A | 7 |
| Mar 31, 2027 | -$0.80 | -$0.90 to -$0.71 | 3 | $500000 | N/A | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 2 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.88.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.77 | -$2.77 | -$2.77 | -$2.77 | -$2.88 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.17 | -$3.17 | -$3.17 | -$3.07 | -$2.95 | N/A |
| Quarter ending Mar 31, 2027 | -$0.80 | -$0.80 | -$0.80 | -$0.80 | -$0.82 | N/A |
Frequently Asked Questions About KYTX
What is the KYTX stock forecast?
Consensus analyst estimates put Kyverna Therapeutics, Inc. Common Stock's EPS at -$2.77 for the fiscal year ending Dec 31, 2026. The consensus rating from 6 analysts is Buy.
How do analysts rate KYTX stock?
Of 6 analysts covering Kyverna Therapeutics, Inc. Common Stock, 2 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from KYTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.77, with estimates from -$3.02 to -$2.62 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.17, with estimates from -$3.74 to -$2.71 from 5 analysts.
What revenue do analysts expect from Kyverna Therapeutics, Inc. Common Stock next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $17.20M, with estimates from $4.30M to $41.09M.
How many analysts cover KYTX?
6 analysts rate Kyverna Therapeutics, Inc. Common Stock stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
KYTX pages: Overview, Earnings, Forecast, Financials, Competitors